Biological Variation of Glycated Hemoglobin: Implications for diabetes screening and monitoring
- Address correspondence and reprint requests to Dr. Eric S. Kilpatrick, Department of Chemical Pathology, Withington Hospital, Nell Lane, Manchester M20 2LR, U.K.
OBJECTIVE To assess the inherent potential of glycated hemoglobin as a screening test for type 2 diabetes by determining the biological variation in nondiabetic subjects.
RESEARCH DESIGN AND METHODS HbA1c values were measured by high-performance liquid chromatography (HPLC) in 12 nondiabetic subjects (7 men and 5 women; median age, 40 years [range, 21–55 years]) on 10 fortnightly occasions. The nondiabetic index of individuality (IOI) for HbA1c (i.e., the square root of the ratio of intra- to interindividual variance) was determined. Any test with an IOI of 1.4 has the most potential in disease screening, while one of 0.6 will be of little value.
RESULTS The analytical variance contributed to 9% of the total test variance, intraindividual variance, 6%; and interindividual variance, 85%. The IOI was, therefore, only 0.27. Thus, nondiabetic HbA1c values vary markedly between subjects, while values in the same individual change little with time. As such, to lie outside the assay reference range, the HbA1c values of some nondiabetic subjects must exceed 12 SD from their usual mean value, while in others a change of only 2 SD would be sufficient.
CONCLUSIONS This fundamental characteristic of HbA1c means that even if analytical methods improve, glycated hemoglobin measurements will always be of limited value when screening for type 2 diabetes. If similar interindividual differences also exist in diabetic subjects, then patients with the same glycemic control may vary by at least 1–2%, which has implications in setting glycated hemoglobin targets.
- Received August 29, 1997.
- Revision received October 13, 1997.
- Accepted October 13, 1997.
- Copyright © 1998 by the American Diabetes Association